The pharmacological profile of DSP-6952, a novel 5-HT 4 receptor partial agonist, was investigated to evaluate the potential use for GI disorders, and to compare its effects in some GI dysfunction models with those of clinically efficacious prokinetic agents. DSP-6952 enhanced gastric motility and caused colonic giant migrating contractions (GMCs) associated with defecation in conscious dogs, having ED 50 value for inducing GMCs of 1.56 mg/kg. DSP-6952 (3-10 mg/kg, i.g.) significantly enhanced colonic transit rate in guinea pigs; this enhancement was antagonized by SB-207266, a selective 5-HT 4 receptor antagonist. DSP-6952 (1-10 mg/kg, p.o.) rapidly increased fecal wet weight without increasing fluid content in mice. Sennoside (30-100 mg/kg, p.o.) also increased fecal wet weight; however, it significantly increased fluid content with diarrhea. DSP-6952 dosedependently improved clonidine-and morphine-induced delay in whole-gut transit in mice (ED 50 = 0.429 mg/kg and 0.310 mg/kg, respectively), which represented atonic and spastic constipation models, respectively. In viscerally hypersensitive rats treated with acetic acid, DSP-6952 (10 mg/kg, i.p., 30 mg/kg, p.o., 30 mg/kg, i.c.) and tegaserod (1 mg/kg, i.p.), but not prucalopride (10 mg/kg, i.p.), significantly inhibited the increase in colorectal distension-induced visceromotor response; these findings suggest that DSP-6952 and tegaserod inhibit visceral hypersensitivity in rats. It was concluded that DSP-6952, a novel and orally available 5-HT 4 receptor agonist, induced colonic GMCs, enhanced colonic transit, increased defecation without inducing diarrhea, improved drug-induced delay in whole-gut transit, and inhibited visceral hypersensitivity in experimental animals. Therefore, DSP-6952 is expected to become a useful drug for treatment of IBS-C and chronic constipation.
Introduction
Constipation is a common gastrointestinal (GI) disorder, in which patients experience unsatisfying defecation associated with infrequent bowel movement, hard stool, and is accompanied by abdominal discomfort (Longstreth et al., 2006) . Constipation is broadly classified into functional constipation, irritable bowel syndrome with constipation (IBS-C), and symptomatic constipation associated with certain disorders, such as Parkinson's disease. In addition, chronic constipation, also called functional constipation is classified into some categories: outlet obstruction, normal-transit, and slow-colonic transit constipation (Sorbera et al., 2004) or habitual, atonic, and spastic constipation (Stieffel, 1951) . IBS also is known as functional bowel disorder characterized by disordered defecation associated with abdominal pain, discomfort, or a change in bowel habits (Longstreth et al., 2006) . Traditional laxatives, such as stimulant laxatives (e.g., sennoside) and saline laxatives (e.g., magnesium oxide), have been widely used thus far (Gershon and Tack, 2007) . Tegaserod, a non-selective 5-HT 4 receptor partial agonist, has been used for treatment of IBS-C and chronic constipation (Camilleri, 2001 ). Prucalopride, a 5-HT 4 full agonist, has been used for treatment of laxative-uncontrolled chronic constipation in women (Garnock-Jones, 2016) . However, after tegaserod was suspended because of an increase of ischemic cardiovascular events, prucalopride is the only 5-HT 4 receptor agonist currently available for the treatment of lower GI tract dysfunctions in Europe and Canada. Therefore, new pharmacological agents are needed to achieve substantial relief of constipation symptoms and abdominal discomfort/pain without diarrhea and cardiovascular side effect.
Recently, we have developed a novel 5-HT 4 receptor partial agonist, DSP-6952, with a favorable cardiovascular safety profile (Fig. 1 , Table 1 ). In this study, we investigated the effects of DSP-6952 in comparison with those of existing prokinetic agents, to evaluate the potential use of DSP-6952 as a candidate drug for treatment of functional bowel disorders, such as IBS-C and chronic constipation. In particular, we investigated the effects of DSP-6952 on GI motility in conscious dogs, colonic transit in guinea pigs, defecation in mice, druginduced delay in whole-gut transit in mice (atonic and spastic constipation models), and viscerally hypersensitive rats (IBS model).
Materials and methods

Animals
Male Slc: Hartley guinea pigs (Japan SLC Inc., Shizuoka), male Slc: ddY mice (Japan SLC Inc.), male Crl: CD Sprague-Dawley (SD) rats (Charles River laboratories Inc., Kanagawa), and male Nosan-Beagle dogs (Naruku Inc., Chiba) were used in this study. All experiments were approved by the Institutional Animal Care and Use Committee at the Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd.
GI motility in conscious dogs
The dogs were anesthetized with sodium pentobarbital and the abdominal cavity was opened under aseptic conditions. Force transducers (F-12IS, Star Medical) were sutured on the serosal surface of the GI tract oriented to the axis of the circular muscle, modified from the method of Itoh et al. (1977) . The force transducers were placed on the gastric antrum at 3 cm from the pyloric ring, and on the colon at 10 cm, 15 cm, and 20 cm distal from the ileocolonic junction. A silicone tube was inserted into the gastric body as a route for the intragastric (i.g.) injection of each drug. The lead wires of the transducers and the tube were taken out of the abdominal cavity and then brought out through a skin incision made between the scapulae. Recording of GI motility was started at least 2 weeks after surgery. The motility was measured with a telemetry system (DAS-800T, Star Medical) and the recorded data were analyzed by a personal computer using a software program (Eight Star, Star Medical). Each test drug was intragastrically administered to the dogs through the implanted tubes at 2 h after feeding. The numbers of colonic giant migrating contractions (GMCs) that occurred for 2 h after drug administration were counted. GMCs, which were defined according to Karaus and Sarna (1987) as isolated high-amplitude colonic contractions running over at least 2 force transducers with rapid propagating velocity, were visually analyzed. The number of defecations that occurred for 2 h after drug administration was confirmed and counted by recorded video data. Occurrence of GMCs (or defecation) in each treatment group was expressed as the number of dogs that produced GMCs (or defecation) to the number of test dogs. The ED 50 value of test drug for the occurrence of GMCs (or defecation) was estimated using the probit method by Stat Preclinica. Gastric motor index was quantified by the determination of the Average of Area, which bounded between the contraction waves and baseline per effective time. In this study, the Average of Area in the 60 min before administration was designated as 100%, and the percentage change in the Average of Area for 2 h after administration was calculated. The gastric motor index was expressed as the mean value and standard deviation. Differences in the gastric motor index between the vehicle group and test drug treatment groups were analyzed using parametric Dunnett's multiple comparison test with P values (two-tailed test) estimated.
Colonic transit in guinea pigs
Guinea pigs were anesthetized with sodium pentobarbital, and the abdomen was opened by midline laparotomy. A polyethylene tube was inserted into the gastric body for drug administration. Moreover, a silicon tube was inserted into the colon for injection of 2.5% Evans blue marker (suspended in 1.5% carboxymethyl cellulose sodium salt aqueous); In brief, a small incision was made in the cecum (1 cm proximal to the cecocolic junction), a silicon tube was implanted through it, and its tip was positioned in the proximal colon (2 cm distal to the cecocolic junction). These tubes in the abdominal cavity were brought out through a skin incision made between the scapulae, and the skin incisions in the abdomen and back were sutured. Animals were then individually housed in cages until experiment. On the fourth day after the surgical operation, unfasted guinea pigs were intragastrically administered the test drugs. In the antagonist experiment, SB-207266 or vehicle (saline) was administered to guinea pigs at the same time as DSP-6952. After 30 min, 1 mL Evans blue marker was injected into the proximal colon through an indwelling tube. Animals were euthanized by decapitation 30 min after administration of Evans blue marker, and the entire colon, from the cecocolic junction to the distal end of the colon, was surgically removed. The full length of the colon and the distance traversed by Evans blue marker from the cecocolic junction were then measured. Colonic transit rate was calculated as follows: Colonic transit rate (%) = [distance traversed by the Evans blue marker (cm)/ full length of the colon (cm)] × 100. When Evans blue marker was discharged in the animal feces, the colonic transit rate was considered to be 100%. Radioligand binding studies were performed using membranes prepared from CHO cells stably transfected with the human 5-HT 4(a) , 5-HT 4(b) , or 5-HT 4(c) receptor splice variants or guinea pig striatum tissue preparation. Ki values were derived from three independent experiments conducted in duplicate.
Defecation in mice
In each experiment, the mice were divided some groups based on body weight. Mouse fecal pellets were collected from each cage (5 mice per cage), and the wet weight was measured at 30, 60, and 120 min after test drug administration. In the experiment involving sennoside, mouse fecal pellets were additionally weighed at 180, 240, and 300 min after administration. The shape of fecal pellets was also examined at each time point. After determination of the wet weight of mice fecal pellets, they were dried in a high-temperature oven, and their dry weight was measured. The wet weight of mouse fecal pellets was recorded at each time point for each cage, and the cumulative fecal wet weight since drug administration was used as "total fecal wet weight". Similarly, the dry weight was recorded at each time point, and the cumulative fecal dry weight was used as "total fecal dry weight". Fluid content of fecal pellets was determined as follows: Fluid content of fecal pellets = 100 × [(total fecal wet weight -total fecal dry weight) / total fecal wet weight]. In each experiment, fluid content of fecal pellets was determined at 0-120 min after administration. In the experiment involving sennoside, fluid content of fecal pellets was additionally determined at 0-300 min after administration. Statistical analysis was performed with Dunnett's multiple-range test.
2.5. Clonidine-and morphine-induced delay in whole-gut transit in mice Animals were fasted for about 21 h prior to test drug administration. The test drug was orally administered to fasted mice by gavage. Clonidine or morphine was subcutaneously administered 30 min after administration of each test drug. Then, each mouse orally received Evans blue marker and was moved into a plastic cage, where the wholegut transit was measured. Whole-gut transit was defined as the time from Evans blue marker administration until its evacuation from the anus. In this study, whole-gut transit measurement in each mouse was finished at 300 min after Evans blue marker administration.
Clonidine-and morphine-induced delay in whole-gut transit was assessed by t-test. Significance of the effect of each test drug on clonidine-and morphine-induced delay in whole-gut transit was determined by Dunnett's multiple-range test. Dose-dependency of the effect of each test drug was evaluated by Jonckheere-Terpstra test. The median effective dose (ED 50 ) was defined as the dose of the test drug that causes 50% improvement in clonidine-or morphine-induced delay in wholegut transit by linear regression analysis with 95% confidence interval.
CRD-induced VMR in viscerally hypersensitive rats treated with acetic acid
Each rat was acclimatized to experimental conditions in an observation cage three times before the experiment. Animals were fasted from the day before the experiment until test drug administration. On the day of the experiment, each rat was anesthetized with isoflurane, and a strain gauge force transducer (F-12IS; Star Medical) was sutured to the external oblique muscle. A flexible polyethylene balloon (5-cm long; Star Medical) with a silicone tube for infusion was then inserted 8 cm into the distal colon and held in place by taping the balloon catheter to the base of the tail. The balloon catheter was composed of a polyethylene tube with a flexible polyethylene balloon. The inserted balloon catheter was attached to a programmable barostat (Distender Series II; G & J Electronics Co., Ltd.) to ensure constant colorectal distension (CRD) pressure. After the surgery, each rat was placed in an observation cage for visceromotor response (VMR) measurement. The strain gauge force transducer was connected to a recording system, and abdominal muscle contractions, which indicate abdominal pain, were recorded for each rat. In addition, abdominal pain behavior (hunching, hump-backed position, licking of the lower abdomen and/or flanks, keeping the abdomen on the floor and the nose curved towards the tail (alpha-position), stretching of the body, and squashing of the lower abdomen against the floor) was checked by visual observation (Wesselmann et al., 1998) . In this study, VMR was determined by counting the number of abdominal muscle contractions with abdominal pain behavior for 10-min at each CRD pressure. Before test drug administration, each rat received 10-min distensions at 0, 20, and 40 mmHg pressure (1st CRD). A 10-min interval was left between distensions. Animals with the following criteria were excluded: the number of 1st CRD-induced VMR at 0 mmHg ≥ 10, and at 40 mmHg < 10 or ≥ 30. The second CRD-induced VMR (2nd CRD) was measured in each rat approximately 60 min after the 1st CRD stimulation. The protocol for the 2nd CRD involved 10-min distension at 0, 20, and 40 mmHg pressure followed by 10-min interval between distensions. Acetic acid (0.6%) infusion started immediately after the 1st CRD measurement. It was infused into the lumen of the colon 8 cm from the anus using a silicone tube and an infusion pump. Each test drug was intraperitoneally, orally, and intracolonically (from the anus using a silicone tube) administered 10 min (i.p.) and 60 min (p.o., and i.c.) before the 2nd CRD measurement, respectively.
Chemicals
, tegaserod maleate (tegaserod), prucalopride, and SB-207266 were synthesized in our laboratories. Clonidine (clonidine hydrochloride; Tokyo Chemical Industry Co., Ltd), morphine (morphine hydrochloride hydrate; Takeda Pharmaceutical Co., Ltd), sennoside (sennoside A; EXTRASYNTHESE S.A.S), and acetic acid (Nakalai tesque Co., Ltd) were commercially purchased.
Results
Effect on GI motility in conscious dogs
Figs. 2-4 show a typical trace of the effects of DSP-6952, tegaserod, and prucalopride on GI motility in a conscious dog. DSP-6952 (1 mg/ kg, i.g.) enhanced gastric motility and clearly altered colonic motility patterns, which caused GMCs associated with defecation within 2 h after treatment. Similarly, tegaserod (3 mg/kg, i.g.) and prucalopride (1 mg/kg, i.g.) enhanced gastric motility and caused colonic GMCs and defecation.
The summary of the effects of DSP-6952, tegaserod, and prucalopride on mean gastric motor index, GMCs, and defecation in conscious dogs is shown in Table 2 . The ED 50 values for the occurrence of GMCs were 1.56 mg/kg (95% confidence interval 0.84-5.13 mg/kg) for DSP-6952, 3.53 mg/kg (95% confidence interval 0.63-534.54 mg/kg) for tegaserod, and 0.08 mg/kg (95% confidence interval 0.01-0.56 mg/kg) for prucalopride. The ED 50 values for occurrence of defecation were 2.87 mg/kg (95% confidence interval 1.46-69.37 mg/kg) for DSP-6952, 4.67 mg/kg (95% confidence interval 2.10-32.26 mg/kg) for tegaserod, and 0.15 mg/kg (95% confidence interval 0.03-0.72 mg/kg) for prucalopride. In addition, Table 2 shows the P values (Dunnett's multiple comparison test) for differences in gastric motor index between the vehicle group and test drug treatment groups. Prucalopride (1 mg/kg) significantly increased gastric motor index, and DSP-6952 and tegaserod tended to increase gastric motor index in a dose-dependent manner.
Effect on colonic transit in guinea pigs
The effect of DSP-6952 on colonic transit rate in guinea pigs is shown in Fig. 5 . The i.g. administration of DSP-6952 at 3 mg/kg and 10 mg/kg significantly enhanced colonic transit rate. In addition, the effect of DSP-6952 (0.3, 1, 3 and 10 mg/kg, i.g.) on colonic transit rate showed a clear dose-dependency (P < 0.0001). The effect of SB-207266, a selective 5-HT 4 receptor antagonist, on DSP-6952-induced enhancement of colonic transit rate in guinea pigs is shown in Fig. 6 . The i.g. administration of DSP-6952 at 10 mg/kg significantly increased colonic transit rate, and this increase was significantly reduced by subcutaneous administration of SB-207266 at 0.01 mg/kg and 0.1 mg/ kg.
Effects on defecation in mice
The effects of test drug on defecation in mice are shown in Fig. 7 . DSP-6952 (0.3-10 mg/kg), tegaserod (1-30 mg/kg), or prucalopride (0.3-10 mg/kg) showed a dose-dependent effect on fecal pellet wet weight at 0-120 min after each administration. DSP-6952 (1-10 mg/ kg), prucalopride (1-10 mg/kg), and tegaserod (10-30 mg/kg) significantly increased total fecal wet weight at 0-120 min. DSP-6952 (0.3-10 mg/kg) and prucalopride (0.3-10 mg/kg) did not increase the fluid content of fecal pellets, whereas tegaserod (10-30 mg/kg) significantly increased the fluid content of fecal pellets at 0-120 min (Table 3 ).
The effect of sennoside (3-100 mg/kg) on fecal pellet wet weight was dose-dependent at 0-300 min; however, it was not dose-dependent at 0-120 min (Fig. 7 ). Sennoside (10-100 mg/kg) significantly increased total fecal wet weight at 0-300 min but not at 0-120 min. In addition, diarrhea with mucus was observed in mice treated with sennoside (10-100 mg/kg) at 180 min after administration. Sennoside (30-100 mg/kg) significantly increased the fluid content of fecal pellets at 0-300 min, but not at 0-120 min (Table 3) .
Effects on clonidine-induced delay in whole-gut transit in mice
The effects of test drugs on clonidine-induced delay in whole-gut transit as an atonic constipation model are shown in Fig. 8 . In each experiment, treatment with clonidine induced a significant delay in whole-gut transit compared to that reported for the saline-treated group. The difference in the mean whole-gut transit between the clonidine-treated and saline-treated groups was more than 30 min in all experiments. DSP-6952 (3 mg/kg), prucalopride (10 mg/kg), and Fig. 2 . Typical trace of the effect of DSP-6952 on GI motility in a conscious dog. Two hours after feeding, DSP-6952 (1 mg/kg) was administered intragastrically to the dog sutured force transducers on the gastric antrum and 3 sites of the colon. ▲: defecation. Fig. 3 . Typical trace of the effect of tegaserod on GI motility in a conscious dog. Two hours after feeding, tegaserod (3 mg/kg) was administered intragastrically to the dog sutured force transducers on the gastric antrum and 3 sites of the colon. ▲: defecation.
tegaserod (3 mg/kg) significantly improved clonidine-induced delay in whole-gut transit. In addition, the effects of DSP-6952 and prucalopride were dose dependent. The ED 50 values (and 95% confidence interval) of DSP-6952 and prucalopride were 0.429 mg/kg (0.0848-2.17 mg/kg) and 0.474 mg/kg (0.134-1.68 mg/kg), respectively. The effect of tegaserod was not dose-dependent at a dose range of 1-30 mg/kg; however, it was dose-dependent at a dose range of 1-3 mg/kg (P-value = 0.0288). The ED 50 of tegaserod (1-3 mg/kg) for improvement of clonidine-induced delay in whole-gut transit was 1.53 mg/kg (95% confidence interval = 0.482-4.83 mg/kg).
Effects on morphine-induced delay in whole-gut transit in mice
The effect of DSP-6952 on morphine-induced delay in whole-gut transit as a spastic constipation model is shown in Fig. 9 . Treatment with morphine induced a significant delay in whole-gut transit, compared to that reported for the saline-treated group. The difference in the mean whole-gut transit between the morphine-treated and salinetreated groups was more than 30 min. The effect of DSP-6952 on morphine-induced delay in whole-gut transit was dose dependent (Pvalue = 0.0448), where DSP-6952 at 10 mg/kg significantly improved the delay. The ED 50 (and 95% confidence interval) of DSP-6952 was 0.31 mg/kg (0.010-9.638 mg/kg).
Effects on CRD-induced VMR in viscerally hypersensitive rats treated with acetic acid
Visceral hypersensitivity was induced by acetic acid infusion. The means of the 2nd CRD-induced VMR at 0, 20, and 40 mmHg for the acetic acid-treated rats (acetic acid group) and distilled water-treated rats (water group) and the P-values are given in Table 4 . Our results showed that acetic acid significantly increased CRD-induced VMR at 20 and 40 mmHg. Based on the smallest P-value, the effects of the test drugs on CRD-induced VMR at 40 mmHg were investigated.
The effects of the test drugs on CRD-induced VMR at 40 mmHg in Fig. 4 . Typical trace of the effect of prucalopride on GI motility in a conscious dog. Two hours after feeding, prucalopride (1 mg/kg) was administered intragastrically to the dog sutured force transducers on the gastric antrum and 3 sites of the colon. ▲: defecation. . Effect of DSP-6952 on colonic transit rate in guinea pigs. Each column represents the mean ± S.D. of colonic transit rate (n = 9, each group). DSP-6952 or vehicle was intragastrically administered to guinea pigs. Thirty minutes later, Evans blue marker was instilled into the proximal colon through an indwelling tube. Animals were euthanized 30 min after injection of Evans blue marker, and the distance traversed by Evans blue marker was measured and its ratio to the full length of the colon was calculated. *P < 0.05, ***P < 0.001, significantly different from the vehicle control group (Dunnett's multiple-range test).
acetic acid-induced visceral hypersensitivity in rats are shown in Fig. 10B . Administration of DSP-6952 (10 mg/kg, i.p.) or tegaserod (1 mg/kg, i.p.) significantly inhibited the increase in CRD-induced VMR at 40 mmHg in acetic acid-treated viscerally hypersensitive rats. Although CRD-induced VMR in the prucalopride (10 mg/kg, i.p.)-treated group was weaker than that in the vehicle (50% PG, i.p.)-treated group at 40 mmHg, the difference was not statistically significant. The effect of oral DSP-6952 on CRD-induced VMR is shown in Fig. 10C . Oral administration of DSP-6952 (30 mg/kg, p.o.) significantly inhibited the increase in CRD-induced VMR. The effect of intracolonic DSP-6952 on CRD-induced VMR is shown in Fig. 10D . Intracolonic administration of DSP-6952 (30 mg/kg, i.c.) significantly inhibited the increase in CRDinduced VMR.
Discussion
Similarities in GI motor patterns and the motility enhancing effect of gastrokinetic agents between dogs and humans have been reported Each column represents the mean ± S.D. of colonic transit rate (n = 9, each group). DSP-6952 (10 mg/kg) or vehicle (0.5% MC) was intragastrically administered to guinea pigs. SB-207266 or vehicle (saline) was subcutaneously administered at the same time as DSP-6952. Thirty minutes later, Evans blue marker was injected into the proximal colon through an indwelling tube. Animals were euthanized 30 min after injection of Evans blue marker, and the distance traversed by Evans blue marker was measured and its ratio to the full length of the colon was calculated. ### P < 0.001, significantly different from the control group (Student's t-test). *P < 0.05, **P < 0.01, significantly different from the DSP-6952 control group (Dunnett's multiple-range test). Fig. 7 . Effect of A) DSP-6952, B) tegaserod, C) prucalopride, and D) sennoside on defecation in mice. Each value represents the mean ± S.D. for the cumulative fecal wet weight (g) at each time point from the time of administration of the test drug (n = 6). Mouse fecal pellets were collected from each cage (5 mice per cage), and the wet weight was determined at the designated time after oral administration. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the vehicle-treated group (Dunnett's multiplerange test). Each value represents the mean ± S.D. for the cumulative fecal fluid content (%) at each time point (n = 6). Mouse fecal pellets were collected from each cage (5 mice per cage), and the wet and dry weights were determined at the designated time after oral administration of the test drugs. The fecal fluid content was determined as follows: Fecal fluid content (%) = 100 × [(total fecal wet weight−total fecal dry weight)/ total fecal wet weight]. P -value was determined using Dunnett multiple comparison test compared with the vehicle group. (Itoh and Sekiguchi, 1983; Coremans et al., 1988) , thus it is useful to investigate the effect of a new prokinetic agent on GI motility in conscious dogs to evaluate its potential for clinical usage. The present study showed that DSP-6952, as well as tegaserod and prucalopride, enhanced gastric motility and caused colonic GMCs associated with defecation in conscious dogs. Based on ED 50 values, the occurrence of GMCs following treatment with DSP-6952 was more potent than that treatment with tegaserod. Colonic GMCs are critical for propagating colonic contents, which seems to be equivalent to the high amplitude propagating contractions in humans. These contractions are extremely strong contractions which sweep around all the way to the rectum, and often trigger a bowel movement. In addition, to further clarify the potential for the treatment of lower GI tract disorders, the effect on Fig. 8 . Effect of A) DSP-6952, B) tegaserod, and C) prucalopride on clonidine-induced delay in whole-gut transit in mice. Each value represents the mean ± S.D. of the wholegut transit time (n = 11 − 14). Clonidine was subcutaneously administrated and Evans blue marker was orally administered 30 min after oral administration of each test drug. The time from administration of Evans blue marker to excretion of the marker in feces was determined. The animals in the control group did not receive clonidine, whereas those in the vehicle group received subcutaneous clonidine 30 min after oral administration of the vehicle (0.5% MC solution). # P < 0.05 compared with the control group (t-test). *P < 0.05 compared with the vehicle group (Dunnett's multiple-range test).
Table 4
Effects of acetic acid on CRD-induced VMR in conscious rats.
Group VMR (P -value)
The number of animals 0 mmHg 20 mmHg 40 mmHg Control 1.80 ± 2.30 14.20 ± 7.11 23.70 ± 4.24 10 Acetic acid 5.67 ± 7.05 22.44 ± 9.55 31.11 ± 7.82 9 (0.1186) (0.0464) (0.0184) VMR was measured by counting the number of abdominal muscle contractions caused by 2nd CRD pressure. VMR is expressed as mean ± S.D. Each rat in the control group was injected with distilled water into the colon, whereas those in the acetic acid-treated group were injected with 0.6% acetic acid into the colon. The P-value was calculated using parametric Dunnett's multiple comparison test compared with the control group. Fig. 9 . Effect of DSP-6952 on morphine-induced delay in whole-gut transit in mice. Each value represents the mean ± S.D. of whole-gut transit time (n = 12 − 14). Morphine was subcutaneously administered and Evans blue marker was orally administered 30 min after oral administration of DSP-6952. The time from administration of Evans blue marker to excretion of the marker in feces was determined. The animals in the control group did not receive morphine, whereas those in the vehicle group received subcutaneous morphine 30 min after oral administration of the vehicle (0.5% MC solution). # P < 0.05 compared with the control group (t-test). *P < 0.05 compared with the vehicle group (Dunnett's multiple-range test).
colonic transit was evaluated in guinea pigs. Our results showed that DSP-6952 dose-dependently increased colonic transit rate, and that this enhancement was antagonized by SB-207266, a selective 5-HT 4 receptor antagonist (Wardle et al., 1996) . Based on these findings, we revealed that DSP-6952 enhanced upper and lower GI motility and colonic transit involved activation of the 5-HT 4 receptor. In particular, as DSP-6952 potently caused colonic GMCs associated with defecation, it was believed that DSP-6952 would be useful in the treatment of disorders associated with constipation. In this study, to further evaluate the potential use of DSP-6952 for treatment of GI disorders, particularly, chronic constipation and IBS-C, we examined the effect of DSP-6952 in various in vivo models of GI disorders. In the study of mice fecal evaluation, results showed that orally administered to DSP-6952, prucalopride, and tegaserod, rapidly induced defecation in mice compared to that reported for sennoside. Moreover, DSP-6952 increased fecal wet weight without affecting the fecal fluid content and inducing severe diarrhea. In contrast, tegaserod slightly increased the fecal fluid content, and sennoside significantly increased the fecal fluid content and induced severe diarrhea. Sennoside, a stimulant laxative, causes active secretion of water and electrolytes, which leads to fluid accumulation in the intestine. In addition, the breakdown products of sennoside act directly as irritants on the colonic wall to induce fluid secretion (Sharkey and Wallace, 2011) . Then, the increase in the filling pressure in the intestine stimulates intestinal peristalsis (Jiang et al., 2015) . Actually, it was reported that sennoside induced severe diarrhea, and its effect typically starts late in clinical studies (Staumont et al., 1988) . Alternatively, 5-HT 4 receptor agonists, such as DSP-6952, directly or indirectly initiate the peristaltic or secretory reflex through the release of acetylcholine, resulting in rapid induction of defecation without severe diarrhea. Prucalopride and tegaserod have been reported to induce only mild transient diarrhea in clinical studies (Camilleri et al., 2009; Layer et al., 2007) . Based on these findings, we expect that DSP-6952 can enhance defecation in humans without producing severe diarrhea.
To further evaluate the efficacy of DSP-6952 in constipation, its effects in drug-induced constipation models were examined. Clonidine, an adrenergic α2 receptor agonist, relaxes the intestine and delays the colonic transit, thus, it has been used to induce atonic constipation (Kojima et al., 2009) . Atonic constipation, which is common in the elderly or bedridden patients, caused by failure of the colon to respond to the normal stimuli for evacuation. Morphine, an opioid μ receptor agonist, inhibits the propulsive movement of the GI tract combined with spastic contraction of the smooth circular muscles, thus, it has been used to induce spastic constipation (Jurna et al., 1996 ; Tucci et al., Fig. 10 . Effect of test drugs on CRD-induced VMR at 40 mmHg in acetic acid-treated viscerally hypersensitive rats. Each value represents the mean ± S.D. of the VMR at 40 mmHg. A): Each rat in the acetic acid-treated group was infused with 0.6% acetic acid into the colon, and each rat in the control group was infused with distilled water (n = 9 or 10). # P < 0.05 compared with the control group at each 2nd CRD (parametric Dunnett's multiple comparison test). B): Each test drug was intraperitoneally administrated in acetic acid-treated rats (n = 10 or 11). *P < 0.05, * *P < 0.01 compared with the vehicle (50% PG)-treated group (parametric Dunnett's multiple comparison test). C): DSP-6952 was orally administrated in acetic acid-treated rats (n = 11 or 12). *P < 0.05 compared with the vehicle (0.5% MC)-treated group (parametric Dunnett's multiple comparison test). D): DSP-6952 was intracolonically administrated in acetic acid-treated rats (n = 8 or 9). *P < 0.05 compared with the vehicle (0.5% MC)-treated group (parametric Dunnett's multiple comparison test).
2008). Spastic constipation results from obstruction of fecal transit secondary by spasmodic contractions of the colon due to stress or other factors. In our experiments, clonidine (0.03 mg/kg, s.c.) and morphine (1 mg/kg, s.c.) significantly delayed the whole-gut transit in mice, which indicated that they were adequate as constipation models. In this study, the clonidine-induced delay was significantly improved by oral administration of DSP-6952 (3 mg/kg), prucalopride (10 mg/kg), and tegaserod (3 mg/kg). DSP-6952 and prucalopride dose-dependently improved the delay in whole-gut transit. However, the effect of tegaserod decreased at high doses of 10 and 30 mg/kg and was not dosedependent. Other studies have reported that tegaserod improves the delay in whole-gut transit at restricted low doses, but not at high doses in mice (Kojima et al., 2009 ). In addition, the accelerating effect of tegaserod on whole-gut transit in healthy humans was not detected at high doses and did not show dose-dependency (Appel et al., 1997) . The ED 50 values of DSP-6952 and prucalopride for improvement of the clonidine-induced delay in whole-gut transit were 0.429 mg/kg and 0.474 mg/kg, respectively. In addition, tegaserod at doses 1 and 3 mg/ kg dose-dependently improved the delay with an ED 50 value of 1.53 mg/kg. Moreover, the ED 50 of DSP-6952 for improvement of morphine-induced delay was 0.310 mg/kg. Based on these findings, it is believed that DSP-6952 would be clinically effective for treatment of spastic and atonic constipation at similar doses; in addition, the clinical dose of DSP-6952 is expected to be lower and of wider range than that of tegaserod.
IBS is characterized by recurrent abdominal pain and altered bowel habits associated with alteration in motility, secretion, and visceral sensations (Mawe et al., 2006) . It is widely accepted that visceral hypersensitivity is associated with abdominal pain, the most common symptom of IBS (Bueno and Fioramonti, 2002; Verne et al., 2001 ). The mechanism underlying visceral hypersensitivity in IBS remains unclear; however, several factors, including inflammation, sensitization after injury, psychosocial stress, can be involved (Mayer and Gebhart, 1994; Posserud et al., 2006) . Recent investigations suggest that the 5-HT signaling pathway plays a significant role in visceral hypersensitivity (Crowell, 2004) . 5-HT 3 receptor antagonists, such as alosetron and ramosetron, have been found to reduce visceral sensitivity via their action on the intrinsic or extrinsic primary afferent neurons; thus, they are used for the treatment of diarrhea-predominant IBS (Humphrey et al., 1999) . Moreover, 5-HT 4 receptor agonists, such as tegaserod and naronapride, have been shown to reduce hypersensitivity to colonic distension in rats (Hoffman et al., 2012) . To evaluate the efficacy of DSP-6952 in IBS, its effect on visceral hypersensitivity was examined using acetic acid to induce colon irritation. First, we confirmed that 0.6% acetic acid significantly increased CRD-induced VMR; therefore, acetic acid could be appropriately used to induce visceral hypersensitivity. We found that intraperitoneal administration of DSP-6952 (10 mg/kg) and tegaserod (1 mg/kg) significantly inhibited the increase in CRD-induced VMR. However, prucalopride merely exhibited any inhibitory effect on CRD-induced VMR. Moreover, oral administration of DSP-6952 significantly inhibited the increase in CRD-induced VMR in the same model. In addition, it has been reported that oral administration of tegaserod (1 and 10 mg/kg) significantly inhibits the increase in CRDinduced VMR in TNBS-or acetic acid-treated rats (Hoffman et al., 2012) . These findings combined with those of our study indicate that DSP-6952, like tegaserod, might have beneficial effects on visceral hypersensitivity in IBS.
Tegaserod, but not prucalopride, was approved for treatment of IBS (Camilleri, 2001; Patel et al., 2004) . The mechanisms of reducing visceral sensitivity by 5-HT 4 receptor agonists and the differences between the effects of these two drugs in IBS patients have not been clarified. However, it was reported that central administration of tegaserod had no inhibitory effect, and 5-HT 4 receptor antagonists partially inhibited the effects of tegaserod in rats with colonic hypersensitivity (Greenwood- Van et al., 2006) . This indicated that peripheral 5-HT 4 receptors, at least in part, are responsible for reducing visceral hypersensitivity. Moreover, it has been reported that intracolonic infusion of 5-HT 4 agonists, such as tegaserod and naronapride, reduced VMR in a dose-dependent manner; in addition, they were more potent upon intracolonic administration than oral administration (Hoffman et al., 2012) . In this study, we showed that intracolonically administered DSP-6952 inhibited visceral hypersensitivity in a dose-dependent manner, at doses similar to the oral doses. These results support the hypothesis that activation of 5-HT 4 receptors on colonic mucosa and primary afferents neurons in the gut alleviate visceral hypersensitivity; however, the precise mechanisms of action are unknown.
Based on these findings, it is believed that DSP-6952 would be effective in the treatment for various types of constipation, such as atonic or spastic constipation and IBS-C. Secretagogue agents, such as laxatives, lubiprostone, and linaclotide, are the only currently approved drugs for treatment of constipation. Therefore, new prokinetic 5-HT 4 receptor agonists are needed to achieve substantial relief of constipation symptoms and normalization of GI motility, and to increase the number of complete spontaneous bowel movements (CSBMs) without diarrhea. Recently, 5-HT 4 receptor agonists have been reported to exhibit beneficial effects not only in GI disorders but also on the cognitive function and neurogenesis (Hagena and Manahan-Vaughan, 2017; Goto et al., 2016) . Therefore, the efficacy of DSP-6952 in various diseases still needs to be investigated in both clinical and non-clinical studies. DSP-6952 is currently under clinical evaluation to determine its efficacy and tolerability in patients with IBS-C in Japan.
Conclusion
This study shows that DSP-6952, a novel 5-HT 4 receptor partial agonist, enhanced gastric motility and induced colonic GMCs associated with defecation, increased colonic transit, rapidly increased defecation without inducing diarrhea, improved clonidine-and morphine-induced delay in whole-gut transit, and inhibited visceral hypersensitivity in experimental animals. These findings indicated that DSP-6952 would be effective in the treatment of various types of constipations including IBS-C by inducing distal propulsion of colonic content and spontaneous defecation without inducing diarrhea.
